鹭燕医药(002788) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was CNY 4,982,869,676.98, representing a 10.04% increase compared to the same period last year[6] - The net profit attributable to shareholders for Q3 2022 was CNY 82,094,778.88, an increase of 3.61% year-on-year[6] - The company reported a basic earnings per share of CNY 0.21 for Q3 2022, up 5.00% from the same period last year[6] - The net profit for the third quarter of 2022 was CNY 251,958,323, an increase of 9.8% compared to CNY 229,058,402 in the same period last year[25] - The total comprehensive income for the quarter was CNY 255,741,712.26, compared to CNY 228,724,810.17 in the prior year, indicating a growth of 11.8%[25] - The company's total profit for the quarter was CNY 332,785,948.04, compared to CNY 305,016,168.31 in the previous year, marking an increase of 9.1%[25] Cash Flow and Assets - The net cash flow from operating activities increased by 123.80% year-on-year, indicating improved operational efficiency and effective cash management[10] - The net cash flow from operating activities was CNY 92,154,381.20, a significant improvement from a negative cash flow of CNY -387,139,805.67 in the previous year[26] - Cash and cash equivalents at the end of the period were CNY 286,140,227.71, down from CNY 374,128,456.22 at the end of the previous year[27] - The company incurred a net cash outflow from investing activities of CNY -208,475,358.79, slightly improved from CNY -214,096,083.22 in the previous year[27] - The net cash flow from financing activities was CNY 94,556,945.34, a decrease from CNY 500,284,035.29 in the same period last year[27] - The total assets at the end of the reporting period were CNY 10,754,928,476.53, reflecting a 7.63% increase from the previous year[6] Shareholder Information - The total number of common stock shareholders at the end of the reporting period is 28,361[12] - Xiamen Maidi Technology Co., Ltd. holds 35.53% of shares, totaling 138,030,674 shares, with 35,907,834 shares pledged[12] - The top 10 shareholders include Xiamen Mingyuan Hongqiao High-tech Venture Capital Partnership with 1.51% (5,881,192 shares) and individual shareholder Li Weiyang with 1.27% (4,936,545 shares)[12] - The total number of shareholders with voting rights restored for preferred shares is 0[13] - The company has reported no participation in margin financing activities among the top 10 shareholders[12] Legal Matters - The company has ongoing legal matters related to its subsidiary Chengdu Hechuang Pharmaceutical Group, involving a total claim of 23.1 million RMB for breach of contract[17] - Chengdu Hechuang has received bankruptcy distribution payments totaling 78.005 million RMB and 55.3911 million RMB from the bankruptcy administrator of Guizhou Dechangxiang Pharmaceutical Co., Ltd.[15] - The company is actively pursuing legal actions to recover losses from Guizhou Mingrun Construction Engineering Co., Ltd., with a claim of 39.6973 million RMB plus interest[18] - The company has a total of 6,000,000 RMB in bank deposits seized as part of the enforcement of a court ruling related to the bankruptcy case[15] - The company is coordinating with multiple parties to resolve execution-related matters and ensure that collateral is prioritized for debt repayment[16] Investments and Growth - The company’s long-term borrowings increased by 49.06% to CNY 333,119,800.00, primarily due to new project loans[9] - The company’s investment properties increased by 406.86% to CNY 24,936,400.00, attributed to acquisitions through judicial auctions[9] - The company has made significant investments in ongoing projects, including modern Chinese medicine production and new pharmaceutical facilities[9] Operating Costs - Total operating costs amounted to ¥13,967,712,770.29, up 10.15% from ¥12,679,853,348.75 year-on-year[24] - Operating profit for the period was ¥331,260,720.17, a slight increase from ¥305,319,751.77 in the previous year[24]